These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 6966292)
21. Phenotypic heterogeneity of Moloney leukemia virus-induced T cel lymphomas. Pepersack L; Lee JC; McEwan R; Ihle JN J Immunol; 1980 Jan; 124(1):279-85. PubMed ID: 6965293 [No Abstract] [Full Text] [Related]
22. [Natural cytotoxic activity in different experimental conditions in hamsters (author's transl)]. Haddada H; Duthu A; de Vaux Saint Cyr C Ann Immunol (Paris); 1980; 131D(2):187-98. PubMed ID: 7469384 [TBL] [Abstract][Full Text] [Related]
23. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study. Seledtsov VI; Taraban VY; Seledtsova GV; Samarin DM; Avdeev IV; Senyukov VV; Kozlov VA Cell Immunol; 1997 Nov; 182(1):12-9. PubMed ID: 9427805 [TBL] [Abstract][Full Text] [Related]
24. Evidence for the suppression of the development of cytotoxic lymphoid cells in tumor immunized mice. Martin WJ; Esber E; Wunderlich JR Fed Proc; 1973 Feb; 32(2):173-9. PubMed ID: 4688656 [No Abstract] [Full Text] [Related]
25. Cell-mediated immune responses to syngeneic ultraviolet-induced tumours. V. Assessment of accessory and antigen-presenting cell capabilities of normal and ultraviolet-irradiated mice in the generation of anti-tumour cytotoxic effector cells in vitro. Lynch DH; Gurish MF; Daynes RA Immunology; 1982 Sep; 47(1):49-59. PubMed ID: 6981587 [TBL] [Abstract][Full Text] [Related]
26. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316 [TBL] [Abstract][Full Text] [Related]
27. Residual immunogenicity of irradiated spleen cell suspensions after a single intravenous injection of sheep red blood cells in mice. Lagrange PH; Hurtrel B; Michel JC Ann Immunol (Paris); 1980; 131D(2):137-51. PubMed ID: 6970541 [TBL] [Abstract][Full Text] [Related]
28. Immune responses to weakly immunogenic virally induced tumors. VI. Comparison of the immune response of the hybrid to the immune responses of the parents reveals "hybrid responsiveness" effect. Devens B; Naor D J Immunol; 1980 Sep; 125(3):988-94. PubMed ID: 6447725 [No Abstract] [Full Text] [Related]
29. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038 [TBL] [Abstract][Full Text] [Related]
30. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. Cohen P; Vourka-Karussis U; Weiss L; Slavin S J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438 [TBL] [Abstract][Full Text] [Related]
31. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro. Cheever MA; Greenberg PD; Fefer A Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668 [TBL] [Abstract][Full Text] [Related]
32. [Suppressor and antineoplastic activity of the bone marrow and spleen cells in aging AKR mice]. Bel'skiĭ IuP; Bel'skaia NV; Danilets MG; Stal'bovskaia ES; Kusmartsev SA Biull Eksp Biol Med; 1999 Apr; 127(4):452-4. PubMed ID: 10367135 [No Abstract] [Full Text] [Related]
33. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
34. Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma. Kawase I; Uemiya M; Yoshimoto T; Ogura T; Hirao F; Yamamura Y Cancer Res; 1981 Feb; 41(2):660-6. PubMed ID: 6969630 [TBL] [Abstract][Full Text] [Related]
35. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape. Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255 [TBL] [Abstract][Full Text] [Related]
36. Functional efficiency of antitumor cytotoxic lymphoid cells. Wunderlich JR; Martin WJ; Macdonald J Isr J Med Sci; 1973 Mar; 9(3):317-23. PubMed ID: 4710039 [No Abstract] [Full Text] [Related]
37. Regulation of the in vitro secondary cell-mediated cytotoxic response against syngeneic FBL-3 leukemia by macrophages. Igarashi T; Teranishi T; Rodrigues D; Yamamura Y Microbiol Immunol; 1980; 24(6):599-72. PubMed ID: 6968022 [TBL] [Abstract][Full Text] [Related]
38. Different antitumor immunity roles of cytokine activated T lymphocytes from naive murine splenocytes and from dendritic cells-based vaccine primed splenocytes: implications for adoptive immunotherapy. Zhang S; Wang Q; Li WF; Wang HY; Zhang HJ; Zhu JJ Eksp Onkol; 2004 Mar; 26(1):55-62. PubMed ID: 15112581 [TBL] [Abstract][Full Text] [Related]
39. [Effect of serum against hematopoietic stem cells (RAMBS) on self-maintaining cells of Rauscher erythroleukemia]. Mechetner EB; Rozinova EN Biull Eksp Biol Med; 1981 Apr; 91(4):476-8. PubMed ID: 6973375 [TBL] [Abstract][Full Text] [Related]
40. T lymphocytes of young and aged rats. I. Distribution, density, and capping of T antigens. Gilman SC; Woda BA; Feldman JD J Immunol; 1981 Jul; 127(1):149-53. PubMed ID: 6972406 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]